Omnicell (NASDAQ:OMCL – Get Free Report) and P3 Health Partners (NASDAQ:PIII – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Volatility & Risk
Omnicell has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.
Valuation and Earnings
This table compares Omnicell and P3 Health Partners”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Omnicell | $1.18 billion | 1.68 | $2.05 million | $0.44 | 99.59 |
| P3 Health Partners | $1.46 billion | 0.02 | -$147.95 million | ($45.20) | -0.08 |
Omnicell has higher earnings, but lower revenue than P3 Health Partners. P3 Health Partners is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent recommendations for Omnicell and P3 Health Partners, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Omnicell | 0 | 1 | 7 | 1 | 3.00 |
| P3 Health Partners | 1 | 2 | 1 | 0 | 2.00 |
Omnicell currently has a consensus target price of $59.86, suggesting a potential upside of 36.60%. P3 Health Partners has a consensus target price of $3.50, suggesting a potential downside of 1.41%. Given Omnicell’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Omnicell is more favorable than P3 Health Partners.
Profitability
This table compares Omnicell and P3 Health Partners’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Omnicell | 1.67% | 4.00% | 2.46% |
| P3 Health Partners | -10.14% | -302.33% | -20.72% |
Institutional and Insider Ownership
97.7% of Omnicell shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 17.8% of P3 Health Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Omnicell beats P3 Health Partners on 13 of the 15 factors compared between the two stocks.
About Omnicell
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
About P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
